Signal Pharma is the first Kosterlitz project to be spun-out from the University of Aberdeen, and is developing new drugs for the treatment of diastolic heart failure
Congratulations to Dr Iain Greig, Prof Matteo Zanda and Prof Michael Frenneaux, who have founded Signal Pharma, a University of Aberdeen spin-out company, with an initial investment of £400k from a local business angel. Signal Pharma will develop novel drugs for the treatment of diastolic heart failure and other cardiovascular conditions, for which there is an unmet medical need. This was the first programme to receive an award from the Kosterlitz pump-priming fund, and has also had generous support from the University Knowledge Exchange and Transfer Fund, the NHS Grampian Endowment Trust and Roemex Ltd, via the development trust. The team wishes to thank all of those who have made this possible, in particular the efforts of the University's Research and Innovation team.